Search Results 421-430 of 16643 for alopecia

1. An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy - Mayo Clinic

   For Part A only: Participants who did not recover from all clinically significant toxicities (excluding alopecia and hematologic toxicities) of any previous ...

2. A Study to Evaluate M7824 with Concurrent Chemoradiation (cCRT) in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   Participants with diabetes Type I, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.

3. Hairy cell leukemia - Doctors and departments - Mayo Clinic

   This slow-growing cancer doesn't always need immediate treatment. When hairy cell leukemia treatment is needed, it usually starts with chemotherapy.

4. A Study to Evaluate PDS0101 and Pembrolizumab Combination to Treat Subjects with HPV16 + Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma - Mayo Clinic

   Subjects with ≤Grade 2 neuropathy and ≤Grade 2 alopecia are an exception to this criterion and may qualify for therapy. Note: If participant received ...

5. Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer - Mayo Clinic

   Note: Subjects with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study. Note: If subjects ...

6. Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the ...

7. Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction - Mayo Clinic

   ... alopecia, unless approved by the principal investigator; biologics or immunotherapy will not be allowed within 28 days prior to, or during, romidepsin ...

8. A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib - Mayo Clinic

   Resolution of all toxicities from prior therapy to ≤ Grade 1 (or patient baseline) within 1 week prior to the first dose of study drug (excluding alopecia ...

9. Study of TJ011133 in Participants With Relapsed/ Refractory Advanced Solid Tumors and Lymphoma - Mayo Clinic

   Not recovered (i.e., to ≤ Grade 1 or to baseline) from AEs emerging from previous treatments (except alopecia or neuropathy). Incomplete recovery from AEs ...

10. Study to Compare the Safety and Effectiveness of Treatment Combinations in Patients with Recurrent Ovarian Cancer - Mayo Clinic

    Note: Patient with Grade ≤ 2 neuropathy or alopecia is an exception to this criterion and may qualify for the study. Patient has a known diagnosis of ...